SCHEMBL5607609

SCHEMBL5607609

NC(Cc1ccc(CNC(=O)c2cccc(F)c2)cc1)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.59
ALDH1A1 P00352 1/20 0.59
KMT2A Q03164 1/20 0.59
SLC7A5 Q01650 4/20 0.54
HPGD P15428 2/20 0.54
TSHR P16473 1/20 0.54
ITGB3 P05106 1/20 0.50
ITGAV P06756 1/20 0.50
ITGA2B P08514 1/20 0.50
PPARG P37231 2/20 0.49
HDAC6 Q9UBN7 2/20 0.49
HDAC2 Q92769 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
EPHX2 P34913 1/20 0.48
NR1H4 Q96RI1 1/20 0.48
ALPI P09923 1/20 0.48
PKM P14618 1/20 0.48
PTGS1 P23219 1/20 0.48
XIAP P98170 1/20 0.48
CFD P00746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5607599 1.00 MEN1 (0.59) MEN1ALDH1A1KMT2ASLC7A5HPGD
SCHEMBL5082554 0.85 SLC7A5 (0.62) SLC7A5PPARGHDAC6HDAC2HDAC8
SCHEMBL5607088 0.85 SLC7A5 (0.62) SLC7A5PPARGHDAC6HDAC2HDAC8
SCHEMBL5607811 0.85 CA1 (0.62) MEN1ALDH1A1KMT2ASLC7A5HPGD
SCHEMBL5607035 0.85 EPHX2 (0.68) SLC7A5PPARGHDAC6HDAC2HDAC8
SCHEMBL5606488 0.85 CA1 (0.62) MEN1ALDH1A1KMT2ASLC7A5ITGB3
SCHEMBL5607029 0.85 EPHX2 (0.68) SLC7A5PPARGHDAC6HDAC2HDAC8
SCHEMBL5607818 0.85 CA1 (0.62) MEN1ALDH1A1KMT2ASLC7A5HPGD
SCHEMBL5606497 0.85 CA1 (0.62) MEN1ALDH1A1KMT2ASLC7A5ITGB3
SCHEMBL5608062 0.84 LMNA (0.56) MEN1ALDH1A1KMT2ASLC7A5PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101400699-A Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions BRISTOL MYERS SQUIBB CO (US) 2009-04-01 CN claimed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 US claimed
CN-101400699-A Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions BRISTOL MYERS SQUIBB CO (US) 2009-04-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS GLP1R, GIPR, IAPP MEN1 808/4885ALDH1A1 4570/4885KMT2A 3688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.